|
T9928 |
Ranibizumab
|
|
VEGFR
|
|
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and n... |
|
T33701 |
NM-3
|
NM-3,isocoumarin,NM 3,Isocoumarin NM-3,NM3 |
Apoptosis
,
Reactive Oxygen Species
|
|
NM-3 is an orally available anti-angiogenic inhibitor with anti-tumour activity.NM-3 is used as a radiation modulator in vitro and in vivo.NM-3 inhibits vascular endothelial growth factor (VEGF), thereby inhibiting the p... |
|
T27028 |
CJ-3-60
|
CJ 3-60,CJ3-60,CJ-360,CJ360,CJ 360 |
|
|
CJ-3-60, an anti-HIF-1alpha agent, inhibits HIF-1alpha and cellular VEGF proteins. |
|
T12650 |
R916562
|
|
TAM Receptor
|
|
|
|
T35492 |
(±)10(11)-DiHDPA
|
|
|
|
(±)10(11)-DiHDPA is produced from cytochrome P450 epoxygenase action on docosahexaenoic acid . It has been shown to inhibit VEGF-induced angiogenesis in mice and may have additional anti-inflammatory and anti-tumor effec... |
|
T10273 |
AhR modulator-1
|
|
Others
|
|
AhR modulator-1 is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. It inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. It also possesses anti-estrog... |
|
T80593 |
Brolucizumab
|
DLX1008,ESBA 1008,RTH258 |
VEGFR
|
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2]. |
|
T68935 |
BMS-645737
|
|
|
|
BMS-645737 is an inhibitor of vascular endothelial growth factor (VEGF) receptor-2 and fibroblast growth factor (FGF) receptor-1. BMS-646737 has anti-angiogenic activity and was evaluated in nonclinical studies as a trea... |
|
T76871 |
Navicixizumab
|
|
|
|
Navicixizumab (OMP-305B83) is a bispecific anti- VEGF and anti- DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peri... |
|
T78064 |
Synstatin (92-119)
|
SSTN92-119 |
Integrin
|
|
Synstatin (92-119) serves as an anti-tumor agent by suppressing angiogenesis and cancer cell invasion, chiefly through the down-regulation of integrin αvβ3 and attenuation of angiogenic growth factor activation, specific... |
|
T74118 |
Roxatidine
|
|
|
|
Roxatidine, the active metabolite of Roxatidine acetate hydrochloride, serves as a histamine H2-receptor antagonist and exhibits anti-ulcer properties. It functions by suppressing the release of histamine, thereby inhibi... |
|
T77108 |
Olinvacimab
|
|
|
|
Olinvacimab (TTAC-0001), a fully human anti-VEGFR2 monoclonal antibody, demonstrates antiangiogenic activity by inhibiting VEGF binding to KDR, with a dissociation constant (K d) of 0.23 nM. It is utilized in research fo... |
|
T71176 |
Atiprimod (free base)
|
|
|
|
Atiprimod is an orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphoryl... |
|
T69599 |
ABT-510
|
|
|
|
ABT-510 is synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascul... |
|
T68324 |
KCN1
|
|
|
|
KCN1, a novel synthetic sulfonamide, is a HIF pathway inhibitor with potential anticancer activity in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. KCN1 specifically inhibited HIF repo... |
|
T76895 |
Abicipar pegol
|
|
|
|
Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, represents a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound is adept ... |
|
T68389 |
LY2457546
|
|
|
|
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 ... |
